Johnson & Johnson (J&J) is in discussions to acquire Intra-Cellular Therapies, a company specialising in central nervous system disorder treatments, as reported by Bloomberg.
The deal could be finalised as early as mid-January 2025, although the confidential talks may not necessarily result in an agreement.
Other potential buyers might also be interested.
Intra-Cellular’s market value has soared to $10bn after a 40% increase in share price in the 12 months to January.
The company is known for its approaches to mental health and neurological disorders, with a major depressive disorder drug currently in late-stage trials.
Its shares rose following a recent settlement with Sandoz over Caplyta, a bipolar depression medication.
Meanwhile, J&J’s market capitalisation reportedly stands at $342bn, following a 12% decline over the same one-year period.
J&J has not commented on the potential acquisition, which would be the biggest biotech transaction in more than a year, highlighting a resurgence in healthcare deals after a slump.
The potential acquisition comes as J&J seeks to bolster its portfolio following the spin-off of its consumer health division and the $13.1bn acquisition of Shockwave Medical, a heart device manufacturer.
The move is part of J&J’s strategy to sustain growth amid challenges such as the impending loss of exclusivity for its psoriasis treatment, Stelara.
In May 2024, J&J expanded its biotech footprint with the $850m acquisition of Proteologix, which focuses on immune-mediated diseases, with additional milestone payments possible.
“Johnson & Johnson in talks to acquire Intra-Cellular Therapies” was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.